LONDON, June 5 (Reuters) - Roche Holding AG's (ROG.VX) experimental arthritis drug Actemra will be considered for approval by a U.S. Food and Drug Administration panel on July 29.
The new drug, which Roche views as a potential blockbuster, will be discussed by the watchdog's Arthritis Advisory Committee, according to the agency's telephone information line. (Reporting by Ben Hirschler)
KABUL (Reuters) - A suicide bomber killed eight American civilians in an attack at a military base in southeastern Afghanistan on Wednesday, one of the highest foreign civilian death tolls in an insurgent strike in the eight-year war.
Critics say the Sept. 11 trials will endanger America's most populated city. Will a $75-million New Year's Eve plan hold up as New York's security template? Full Article
Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
